The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study
Open accessAbstract
BACKGROUND: A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in 2010, on the basis of its safety and immunogenicity. This vaccine is now being deployed across the African meningitis belt. We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic. METHODS: We obtained data for the incidence of meningitis before and after vaccination from national records between January, 2009, and June, 2012. In 2012, surveillance was enhanced in regions where vaccination with PsA-TT had been undertaken in 2011, and in one district where a reactive vaccination campaign in response to an outbreak of meningitis was undertaken. Meningococcal carriage was studied in an age-stratified sample of residents aged 1-29 years of a rural area roughly 13-15 and 2-4 months before and 4-6 months after vaccination. Meningococci obtained from cerebrospinal fluid or oropharyngeal swabs were characterised by conventional microbiological and molecular methods. FINDINGS: Roughly 1·8 million individuals aged 1-29 years received one dose of PsA-TT during a vaccination campaign in three regions of Chad in and around the capital N'Djamena during 10 days in December, 2011. The incidence of meningitis during the 2012 meningitis season in these three regions was 2·48 per 100,000 (57 cases in the 2·3 million population), whereas in regions without mass vaccination, incidence was 43·8 per 100,000 (3809 cases per 8·7 million population), a 94% difference in crude incidence (p<0·0001), and an incidence rate ratio of 0·096 (95% CI 0·046-0·198). Despite enhanced surveillance, no case of serogroup A meningococcal meningitis was reported in the three vaccinated regions. 32 serogroup A carriers were identified in 4278 age-stratified individuals (0·75%) living in a rural area near the capital 2-4 months before vaccination, whereas only one serogroup A meningococcus was isolated in 5001 people living in the same community 4-6 months after vaccination (adjusted odds ratio 0·019, 95% CI 0·002-0·138; p<0·0001). INTERPRETATION: PSA-TT was highly effective at prevention of serogroup A invasive meningococcal disease and carriage in Chad. How long this protection will persist needs to be established. FUNDING: The Bill & Melinda Gates Foundation, the Wellcome Trust, and Médecins Sans Frontères.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maiden, M. C., & Stuart, J. M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08679-8 · Cited by 418
Self-citationMeningococcal carriage and disease—Population biology and evolution
Caugant, D. A., & Maiden, M. C. J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.061 · Cited by 381
Self-citationImpact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity
Kristiansen, P. A., Diomandé, F., Ba, A. K., Sanou, I., Ouédraogo, A., Ouédraogo, R., Sangaré, L., Kandolo, D., Aké, F., Saga, I. M., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis892 · Cited by 212
Self-citationImmunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans
Sow, S. O., Okoko, B. J., Diallo, A., Viviani, S., Borrow, R., Carlone, G., Tapia, M., Akinsola, A. K., Arduin, P., Findlow, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003812 · Cited by 178
Bennett, J. S., Jolley, K. A., Earle, S. G., Corton, C., Bentley, S. D., Parkhill, J., & Maiden, M. C. J. (2012) · Microbiology · doi:10.1099/mic.0.056077-0 · Cited by 177
Self-citationClaus, H., Maiden, M. C. J., Maag, R., Frosch, M., & Vogel, U. (2002) · Microbiology · doi:10.1099/00221287-148-6-1813 · Cited by 176
Self-citationNovak, R. T., Kambou, J. L., Diomandé, F. V., Tarbangdo, T. F., Ouédraogo-Traoré, R., Sangaré, L., Lingani, C., Martin, S. W., Hatcher, C., Mayer, L. W., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70168-8 · Cited by 158
Self-citationWang, X., Theodore, M. J., Mair, R. D., Trujillo-Lopez, E., du Plessis, M., Wolter, N., Baughman, A. L., Hatcher, C., Vuong, J. T., Lott, L., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.06087-11 · Cited by 149
Nicolas, P., Norheim, G., Garnotel, É., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5129-5135.2005 · Cited by 102
Djingarey, M. H., Barry, R., Bonkoungou, M., Tiendrebeogo, S. R. M., Sebgo, R., Kandolo, D., Lingani, C., Préziosi, M., ZUBER, P. L. F., Perea, W., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.073 · Cited by 96
Self-citation
Research works printed but not linked: 16
- Lapeyssonie, 1963, The meningococcal meningitis in Africa, Bull World Health Org, 28, 3
- Ledentu, 1941, Cerebrospinal meningitis in French Equatorial Africa during the first half of 1939, Bull Off Int d'Hyg Publ, 3, 421
- Sirol, 1969, Some new aspects of purulent meningitis in Sahelian Africa. Clinical, bacteriological and therapeutic study of 368 cases observed in 1969 at Fort-Lamy (Tchad), Med Tropicale, 29, 443
- Garcia, 2004, Outbreak of meningitis in the province of Logone occidental (Chad): descriptive study using health ministry data from 1998 to 2001, Bull Soc Path Exot, 97, 183
- Bregani, 2006, The 2001 meningitis epidemic in south Chad, Minerva Med, 97, 161
- 2010, Meningitis in Chad, Niger, and Nigeria: 2009 epidemic season, Wkly Epidemiol Rec, 8, 57
- Riou, 1996, A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995, Bull World Health Org, 74, 181
- Caugant, 2012, Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine, PLoS One, 7, e46019, 10.1371/journal.pone.0046019 · doi:10.1371/journal.pone.0046019
- Labrie, 2010, Whole cell vaccines for the meningococcus: lessons from an idea for which time has gone, Hum Vaccin, 6, 360, 10.4161/hv.6.4.11055 · doi:10.4161/hv.6.4.11055
- Spiegel, 1993, Effect of 2 vaccination strategies on developments during the epidemic of meningococcal A meningitis in N'Djamena (Chad) in 1988, Bull World Health Org, 71, 311
- Lengeler, 1995, The 1990 meningococcal meningitis epidemic of Sarh (Chad): how useful was an earlier mass vaccination, Acta Tropica, 59, 211, 10.1016/0001-706X(95)00081-O · doi:10.1016/0001-706x(95)00081-o
- Massenet, 2011, Epidemic meningococcal meningitis, Cameroon, Emerg Infect Dis, 17, 2002, 10.3201/eid1711.110468 · doi:10.3201/eid1711.110468
- Suker, 1994, The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation, Mol Microbiol, 12, 253, 10.1111/j.1365-2958.1994.tb01014.x · doi:10.1111/j.1365-2958.1994.tb01014.x
- Kim, 2012, Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010, PLoS One, 7, e29116, 10.1371/journal.pone.0029116 · doi:10.1371/journal.pone.0029116
- Caini, 2013, From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010–January 2012, Vaccine, 31, 1597, 10.1016/j.vaccine.2013.01.015 · doi:10.1016/j.vaccine.2013.01.015
- Altmann, 2013, Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt, Vaccine, 31, 1453, 10.1016/j.vaccine.2012.12.035 · doi:10.1016/j.vaccine.2012.12.035
Cited by
The contribution of vaccination to global health: past, present and future
Greenwood, B. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0433 · Cited by 979
Self-citationImpact of Vaccines; Health, Economic and Social Perspectives
Rodrigues, C. M. C., & Plotkin, S. A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01526 · Cited by 737
After 2015: infectious diseases in a new era of health and development
Dye, C. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0426 · Cited by 361
Mbaeyi, S. A., Bozio, C. H., Duffy, J., Rubin, L. G., Hariri, S., Stephens, D. S., & MacNeil, J. R. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6909a1 · Cited by 321
Community-acquired bacterial meningitis
van de Beek, D., Brouwer, M., Hasbun, R., Koedel, U., Whitney, C. G., & Wijdicks, E. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.74 · Cited by 312
Metadata
- Authors
- Daugla, D., Gami, J., Gamougam, K., Naibei, N., Mbainadji, L., Narbé, M., Toralta, J., Kodbesse, B., Ngadoua, C., Coldiron, M., Fermon, F., Page, A.-L., Djingarey, M., Hugonnet, S., Harrison, O., Rebbetts, L., Tekletsion, Y., Watkins, E., Hill, D., Caugant, D., Chandramohan, D., Hassan-King, M., Manigart, O., Nascimento, M., Woukeu, A., Trotter, C., Stuart, J., Maiden, M., & Greenwood, B.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 383
- Issue
- 9911
- Pages
- 40-47
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2047179190
- Cited by
- 256
- References
- 14
- FWCI
- 30.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. https://app.cochat.ai/papers/10.1016/s0140-6736(13)61612-8
- The paper
- Daugla, D., Gami, J., Gamougam, K., Naibei, N., Mbainadji, L., Narbé, M., Toralta, J., Kodbesse, B., Ngadoua, C., Coldiron, M., Fermon, F., Page, A.-L., Djingarey, M., Hugonnet, S., Harrison, O., Rebbetts, L., Tekletsion, Y., Watkins, E., Hill, D., . . . Greenwood, B. (2014). Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. The Lancet. https://doi.org/10.1016/s0140-6736(13)61612-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.